Acei (DrugBank: -)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 66 | IgA腎症 | 5 |
| 224 | 紫斑病性腎炎 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02571842 (ClinicalTrials.gov) | January 2012 | 6/10/2015 | Rituximab in Recurrent IgA Nephropathy | A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology | Recurrent IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids | Chulalongkorn University | NULL | Recruiting | 18 Years | 70 Years | Both | 30 | Phase 4 | Thailand |
| 2 | ChiCTR-TRC-09000338 | 2009-04-01 | 2009-02-23 | Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy | Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy | IgA nephropathy | Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ; | The First Affiliated Hospital of Zhejiang University | NULL | Completed | 18 | 70 | Male | Group A:60;Group B:60; | China | |
| 3 | ChiCTR-TRC-06000004 | 2006-01-01 | 2006-09-14 | ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial | ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial | primary IgA nephropathy | group 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB; | The First Hospital, Peking University | NULL | Completed | 16 | 65 | Both | group 1:78;group 2:78; | China | |
| 4 | NCT00378443 (ClinicalTrials.gov) | January 2006 | 19/9/2006 | ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT | Glomerulonephritis, IGA | Drug: prednisone + Inhibace/Cozaar;Drug: Inhibace/Cozaar | Peking University | NULL | Active, not recruiting | 16 Years | 65 Years | Both | N/A | NULL | ||
| 5 | NCT00318474 (ClinicalTrials.gov) | January 2002 | 24/4/2006 | Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy | A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy | IgA Nephropathy | Drug: Mycophenolate Mofetil (MMF);Drug: MMF Placebo;Drug: ACEi;Drug: FOS | St. Joseph's Hospital and Medical Center, Phoenix | NULL | Terminated | 7 Years | 70 Years | All | 184 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02532790 (ClinicalTrials.gov) | August 2015 | 20/8/2015 | The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children | The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children | Henoch-Schoenlein Purpura Nephritis | Drug: Prednisone;Drug: ACEI | Nanjing Children's Hospital | NULL | Recruiting | 2 Years | 16 Years | All | 100 | Phase 2 | China |
| 2 | NCT02532777 (ClinicalTrials.gov) | August 2015 | 20/8/2015 | The Research of Standard Diagnosis and Treatment for HSPN in Children | The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children | Henoch-Schoenlein Purpura Nephritis | Drug: Prednisone;Drug: Cyclophosphamide(CTX);Drug: Mycophenolate mofetil(MMF);Drug: Leflunomide(LEF);Drug: Angiotensin-converting enzyme inhibitor(ACEI);Drug: Methylprednisolone | Nanjing Children's Hospital | NULL | Recruiting | 2 Years | 16 Years | All | 100 | Phase 2 | China |